NCT07439744

NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status

Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight/Obese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: National Science and Technology Council, Taiwan · Other Government
• Sex: All
• Age: 18 Years – 54 Years
• Healthy volunteers: Not accepted

Summary

A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.

Conditions

• Obese Adults
• MDD

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Eicosapentaenoic acid (omega-3 fatty acid)	25 participants are assigned
DIETARY_SUPPLEMENT	Placebo	25 participants are assigned

Timeline

• Start date: 2025-03-01
• Primary completion: 2027-03-01
• Completion: 2027-12-01
• First posted: 2026-02-27
• Last updated: 2026-02-27

Locations

1 site across 1 country: Taiwan